Celldex’s mAb fails to show benefit in Phase II prurigo nodularis trial
Celldex said its subcutaneous monoclonal antibody barzolvolimab failed in a Phase II randomized, double-blind, placebo-controlled trial in prurigo nodularis (NCT06366750). Patients did not achieve significant improvement on the WI-NRS at week 12 versus placebo, and key secondary endpoints also missed. Celldex is discontinuing the PN Phase II study; stock was expected to fall at the open.
How this was made
The 30-second read
Why it matters
The Phase II PN trial miss on primary and key secondary endpoints, despite strong pharmacodynamic tryptase suppression, leads Celldex to discontinue the PN Phase II program while maintaining confidence in safety and development in other indications.
Market read
This is a direct clinical development setback for Celldex in PN, with immediate trading relevance due to discontinuation of the Phase II study.
What to watch
The article notes a prior intravenous Phase Ib signal; traders may weigh whether route of administration, dosing, or patient selection differences could matter for future studies despite this discontinuation.
Background
Barzolvolimab is a humanized mAb designed to bind KIT on mast cells; Celldex previously reported a promising signal in an intravenous Phase Ib study.
Ticker impact
Celldex reports barzolvolimab failed to improve WI-NRS itch scores at week 12 versus placebo in Phase II PN, and will discontinue the study.
Likely negative near-term reaction and higher uncertainty around future clinical timelines for PN; magnitude depends on market expectations already priced in.
The article discloses a randomized, double-blind placebo-controlled miss on primary and key secondary endpoints, plus a decision to discontinue the Phase II program.
Market effects
Adds evidence that mast-cell KIT targeting may not translate to efficacy in PN, potentially affecting sentiment toward similar immunology approaches in dermatology.
No specific regional market catalyst beyond Nasdaq-listed Celldex reaction.
PN epidemiology and competitive landscape discussion may influence global dermatology biotech sentiment, but the actionable driver is Celldex-specific trial failure.
Counterpoint
The drug showed target engagement via rapid tryptase suppression, so the failure could be interpreted as biology-specific to PN rather than a total platform breakdown.
Key entities
- companyCelldex
Nasdaq-listed biotech running barzolvolimab Phase II in prurigo nodularis and discontinuing the program after failure.
- drugbarzolvolimab
Humanized monoclonal antibody targeting KIT on mast cells; failed to improve itch/lesions in Phase II PN.
- indicationprurigo nodularis (PN)
Chronic nodular prurigo with unmet need; trial endpoints include WI-NRS itch score and IGA-CPNG-S stage.
